Post-Q3 Selloff in Celgene (CELG) Probably Correction Following Recent Run - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Celgene Reports Third Quarter 2015 Operating and Financial Results
November 5, 2015 7:31 AM ESTOver 150 Abstracts Expected at Medical Congresses in Fourth Quarter Completed Two Major Transactions in the Quarter: Receptos and Juno Therapeutics Key Drivers On-Track Supporting Industry-Leading Growth Including Acceleration of Mid- and Late-Stage Clinical Programs
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $2,313 million for the third quarter of 2015, an 18 percent increase from the same period in 2014. The negative net impact of currency on net product sales was 2 percent. Third quarter... More
